Home > Insider Trading > Filing (0001171843-22-004440)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1738021	Compass Therapeutics Inc.	CMPX	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1591464	J. Thomas Schuetz	C/O Compass Therapeutics, Inc. 80 Guest St., Suite 601 Boston MA 02135	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2022-06-21	20,000	$2.80	5,331,873	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct

Footnotes

The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $2.78 to $2.81 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above.
194,345 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 78,225 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 116,120 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 600,000 of the shares represents restricted stock units ("RSU") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on November 15, 2022.